PATENT

HE UNITED STATES PATENT AND TRADEMARK OFFICE

Docket No.: POUSTKA-2

In re Application of:

ANNEMARIE POUSTKA et al.

Serial No.: 09/880,688

Filed: June 13, 2001

For: METHOD AND DEVICES FOR APPLYING

SUBSTANCES TO A SUPPORT,

ESPECIALLY MONOMERS FOR THE

COMBINATORIAL SYNTHESIS OF

MOLECULE LIBRARIES

Examiner: J.D. Epperson

Group Art Unit: 163 RECEIV

JAN 3 0 2004 TECH CENTER 600/2001

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

U.S. Patent and Trademark Office **Box Sequence** P.O. Box 2327 Arlington, VA 22202

09880688

SIR:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202 on January 20, 2004. (Date)

URSULA B. DAY

(Name of Registered Representative)


eu. 20 200 Date of Signature

This communication is in response to the Official Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, dated October September 24, 2003, having a shortened period for response terminating October 24, 2003.

01/29/2004 MRLANCO 00000006 060502

475.00 DA 61 FC:2253

DATE:



Docket No.: POUSTKA-2 Serial No.: 09/880,688

The Commissioner is hereby petitioned to extend the period for response

to above-referenced Official Action by THREE months until January 26, 2004.

[X] Accompanying this amendment is the appropriate fee of \$475.00

pursuant to 37 C.F.R. §1.17(c) and 37 C.F.R. §1.136(a).

[X] The Commissioner is hereby also authorized to charge any fees which

may be required during the pendency of this application, including any

patent application processing fees under 37 C.F.R. 1.17, and any filing

fees under 37 C.F.R. 1.16, including presentation of extra claims, or credit

any overpayment to Deposit Account No: 06-0502.

Please amend this application as follows:

IN THE SPECIFICATION:

Amend the specification with the sequence listing provided herewith in CRF and

paper form.

2